Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 845928

Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation


Radić Antolic, Margareta; Horvat, Ivana; Serventi Seiwerth, Ranka; Vrhovac, Radovan; Sertic, Dubravka; Nemet, Damir; Zadro, Renata
Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation // Leukemia&Lymphoma 2015., East and West: Linking Knowledge and Practice
Dubrovnik, Hrvatska, 2015. (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 845928 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation

Autori
Radić Antolic, Margareta ; Horvat, Ivana ; Serventi Seiwerth, Ranka ; Vrhovac, Radovan ; Sertic, Dubravka ; Nemet, Damir ; Zadro, Renata

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
Leukemia&Lymphoma 2015., East and West: Linking Knowledge and Practice

Mjesto i datum
Dubrovnik, Hrvatska, 23.09.2015. - 27.09.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Mutated NPM1; FLT3 mutation; cytogenetically normal AML; minimal residual disease

Sažetak
Cytogenetically normal acute myeloid leukemia (CN- AML) belongs to standard-risk group, but molecular markers like NPM1 mutation and FLT3 mutation can change this to favourable or poor risk group. The aim of this study was quantitative assessment of minimal residual disease in CN-AML carrying NPM1 mutation A (NPM1A) with or without FLT3- ITD mutation. The study included 14 CN-AML patients (10F/4M), median age 52 years (range 34-72). Bone marrow aspirate at diagnosis and in follow up was used for molecular analysis. RQ-PCR was used to quantitate NPM1A (Ipsogen, France) while FLT3-ITD was detected by RT-PCR (Nakao et al, Leukemia 1996). Hematological parameters at diagnosis were as follows: leucocyte count median 29.0 x109/L (range 1.4-180.5), bone marrow blasts median 49% (range15-90), anemia and thrombocytopenia. Median follow up was 13 months (range 2-43). Mutated NPM1A normalized copy number (NCN) at diagnosis was 41882 (range 2736-131560), 6/14 patients were FLT3-ITD positive. After induction therapy all patients achieved hematological remission ; 8/14 patients remained NPM1A positive (NCN range 1-6370), among them 3 were at diagnosis FLT3-ITD negative patients, 3 patients who lost FLT3-ITD positive status and 2 patients who were still FLT3-ITD positive and relapsed after 2 months. Among 11 patients who were alive after consolidation therapy, 8 patients underwent and 2 patients were planned for stem cell transplantation. Among transplanted patients (median follow up 22 months, range 7-38), 5 are NPM1A negative while 2 patients who demonstrated considerable NPM1A positivity after induction and consolidation therapy still have detectable low NPM1A. In conclusion, although it is known that mutated NPM1 is not a parameter for risk stratification in FLT3 mutated CN-AML, quantitative measurement of mutated NPM1 is more reliable than detection of mutated FLT3 in molecular monitoring and follow up of patients as well as in relapse prediction.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb


Citiraj ovu publikaciju:

Radić Antolic, Margareta; Horvat, Ivana; Serventi Seiwerth, Ranka; Vrhovac, Radovan; Sertic, Dubravka; Nemet, Damir; Zadro, Renata
Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation // Leukemia&Lymphoma 2015., East and West: Linking Knowledge and Practice
Dubrovnik, Hrvatska, 2015. (poster, međunarodna recenzija, sažetak, znanstveni)
Radić Antolic, M., Horvat, I., Serventi Seiwerth, R., Vrhovac, R., Sertic, D., Nemet, D. & Zadro, R. (2015) Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation. U: Leukemia&Lymphoma 2015., East and West: Linking Knowledge and Practice.
@article{article, author = {Radi\'{c} Antolic, Margareta and Horvat, Ivana and Serventi Seiwerth, Ranka and Vrhovac, Radovan and Sertic, Dubravka and Nemet, Damir and Zadro, Renata}, year = {2015}, keywords = {Mutated NPM1, FLT3 mutation, cytogenetically normal AML, minimal residual disease}, title = {Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation}, keyword = {Mutated NPM1, FLT3 mutation, cytogenetically normal AML, minimal residual disease}, publisherplace = {Dubrovnik, Hrvatska} }
@article{article, author = {Radi\'{c} Antolic, Margareta and Horvat, Ivana and Serventi Seiwerth, Ranka and Vrhovac, Radovan and Sertic, Dubravka and Nemet, Damir and Zadro, Renata}, year = {2015}, keywords = {Mutated NPM1, FLT3 mutation, cytogenetically normal AML, minimal residual disease}, title = {Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation}, keyword = {Mutated NPM1, FLT3 mutation, cytogenetically normal AML, minimal residual disease}, publisherplace = {Dubrovnik, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font